Lilly's Phase II results in Alzheimer's disease have most experts saying donanemab is done - Yahoo Finance
clinicaltrialsarena.comSubmitted by clinicaltrialsarena4434 in business
Eli Lilly’s donanemab for early symptomatic Alzheimer’s disease (AD) has most experts dubious of the drug’s clinical benefit due to marginal and mixed Phase ...